ADMA FY 2025 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$510M+19.6% YoY

Gross Profit

$293M57.4% margin

Operating Income

$191M37.5% margin

Net Income

$147M28.8% margin

EPS (Diluted)

$0.60

Cash Flow

Operating Cash Flow

$50M

Free Cash Flow

$28M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$624M

Total Liabilities

$147M

Stockholders' Equity

$477M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$510M	$426M	+19.6%
Gross Profit	$293M	$220M	+33.3%
Operating Income	$191M	$139M	+37.7%
Net Income	$147M	$198M	-25.7%